Literature DB >> 14604566

Superiority of varicella skin test antigen over purified varicella-zoster virus glycoproteins in monitoring booster response to Oka varicella vaccine.

Hitoshi Sato1, Jun ichi Yamamura, Seiji Kageyama, Masahiko Kurokawa, Kimiyasu Shiraki.   

Abstract

Varicella skin test antigen has been developed based on the induction of delayed-type hypersensitivity (DTH) to varicella-zoster virus (VZV). The booster immune response to Oka varicella vaccine was assessed by cutaneous reactivity to purified VZV glycoprotein complexes, gB, gE:gI, gH:gL, and varicella skin test antigen. Skin tests with these antigens significantly augmented antibody production to glycoproteins and VZV antigen resulting in no further augmentation by the subsequent vaccination. All glycoprotein complexes induced the cutaneous reaction similarly to varicella skin test antigen. Cutaneous reaction to glycoproteins and varicella skin test antigen was boosted after vaccination. However, the magnitude of cutaneous reaction to each glycoprotein complex before and after vaccination was rich in variety. These results indicated that skin test with varicella skin test antigen is a more suitable indicator in monitoring cell-mediated immunity to VZV than that using purified glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604566     DOI: 10.1016/s0264-410x(03)00542-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 2.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

3.  Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster.

Authors:  Y Okuno; Y Takao; Y Miyazaki; F Ohnishi; M Okeda; S Yano; H Kumihashi; Y Gomi; K Maeda; T Ishikawa; Y Mori; H Asada; H Iso; K Yamanishi
Journal:  Epidemiol Infect       Date:  2012-12-10       Impact factor: 4.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.